Tofacitinib is an oral inhibitor of Janus kinase (JAK) that selectively targets JAK1 and JAK3 and induces a modulation of the immune response.1 Tofacitinib has shown good results in patients with rheumatoid arthritis and inflammatory bowel disease and has a safety profile similar to that of tumor necrosis factor blockers; the most frequent adverse events are infections. Herein we report the first case to our knowledge of extensive cutaneous human papillomavirus (HPV) infection occurring shortly after initiation of tofacitinib therapy.
Brunet-Possenti F, Charpentier C, Bouhnik Y, et al. Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy. JAMA Dermatol. 2019;155(5):629–631. doi:10.1001/jamadermatol.2018.5528
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: